Shanghai Acebright Buys 10% in Israel based Nasvax

Acebright Holdings Ltd. will invest $1 million in NasVax for a 10% stake in the company. NasVax is developing two novel drugs, an immunotherapy and a treatment for Alzheimer's.  Shanghai Acebright, a subsidiary of Acebright holdings, produces treatments for cancer and autoimmune diseases, may also participate in future NasVax offering

Enter your email address: Delivered by FeedBurner